PTU - Polskie Towarzystwo Urologiczne
list of articles:

The characteristic of solifenacin and fesoterodine with regard to their clinical efficacy, tolerability and safety in the treatment of overactive bladder
Article published in Urologia Polska 2008/61/4.


Andrzej Wróbel1, Tomasz Rechberger1, Paweł Kieres2
1II Klinika Ginekologii Uniwersytetu Medycznego w Lublinie
2Oddział Urologiczny im. ¦w. Rafała, Wojewódzki Specjalistyczny Zespół Opieki Zdrowotnej GruĽlicy i Chorób Płuc w Kielcach


urinary bladder solifenacin fesoterodine overactive bladder pharmacotherapy


Antimuscarinics such as solifenacin or fesoterodine achieve a good balance of efficacy and tolerability and as a consequence are associated
with good long-term patient satisfaction. The therapeutic profile however may differ because various antimuscarinic drugs have
different affinity to the five subtypes of muscarinic receptors that represent targets for OAB treatment (mainly M2 and M3). Because
of the lack of head-to-head randomized double-blinded, placebo-controlled studies we tried to perform indirect comparison of these
two new-generation antimuscarinics with regard to their efficacy, tolerability and safety in the OAB treatment.


  1. Kelleher CI, Cardozo I, Chapple CR et al: Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. BJU Int 2005, 95, 81-85.
  2. Cardozo L, Lisec M, Millard R et al: Randomized, double blind placebo controlled trial of the once daily antimuscatinic agent solifenacin succinate in patients with overactive bladder. J Urol 2004, 172, 1919-1924.
  3. Brunton S, Kuritzky L: Recent developments in the management of overactive bladder: focus on the efficacy and tolerability of once daily solifenacin succinate 5 mg. Curr Med Res Opin 2005, 21, 71-80.
  4. Chapple CR, Rechberger T, Shukri S et al: Randomized, doubleblind placebo and tolterodine-controlled trial of the once daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int 2004, 93, 303-310.
  5. Abrams P, Swift S: Solifenacin is effective for the treatment of OAB dry patients; a pooled analysis. Eur Urol 2005, 48, 483-487.
  6. Chapple CR, Martinez-Garcia R, Selvagii L et al: A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 2005, 23, 25-34.
  7. Haab F, Cardozo I, Chapple C, Rider AM: Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome. Eur Urol 2005, 47, 376-384.
  8. Kreder K, Mayne C, Jonas U: Long-term safety, tolerability and efficacy of extended -release tolterodine in the treatment of overactive bladder. Eur Urol 2002, 41, 588-595.
  9. Abrams P, Malone – Lee J, Jacquetin B: Twelve – month treatment of overactive bladder: efficacy and tolerability of tolterodine. Drugs Aging 2001, 18, 551-560.
  10. Appell RA, Abrams P, Drutz HP et al: Treatment of overactive bladder: long-term tolerability and efficacy of tolterodine. World J Urol 2001, 19, 141-147.
  11. Cole P: Fesoterodine, an advanced antimuscarinic for the treatment of overactive bladder: a safety update. Drugs Future 2004, 29, 715-720.
  12. Postlind H, Danielson A, Lindgren A: Tolterodine, a new muscarinic receptor antagonist, is metabolized by cytochromes P450 2D6 and 3A in human liver microsomes. Drug Metab Dispos 1998, 26, 289-293.
  13. Sachse R, Cawello W, Haag MC: Dose – proportional pharmacokinetics of the new antimuscarinic fesoterodine. Naunyn-Schmied Arch Pharmacol 2003, 367, 115.
  14. Cawello W, Auer S, Hammes W: Multiple dose pharmacokinetics of fesoterodine in human subjects. Arch Pharmacol 2002, 365, 110.
  15. Nitti V, Wiatrak M, Kreitman L, Lipsitz D: Fesoterodine is an effective antimuscarinic for patients with overactive bladder (OAB): results of a phase 2 trial. Paper presented at International Continence Society, Montreal, Canada, August 31 – September 2, 2005.
  16. Chapple Ch, Kerrebroeck P, Tubaro A et al: Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. Eur Urol 2007, 52, 1204-1212.
  17. Nitti V, Dmochowski R, Sand P, Forst H-T: Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome. J Urol 2007, 178, 2488-2494.
  18. van Kerrebroeck P, Kreder K, Jonas U et al: Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urol 2001, 57, 414.
  19. Rovner ES, Wein AJ: Once-daily, extended-release formulations of antimuscarinic agents in the treatment of overactive bladder: a review. Eur Urol 2002, 41, 6.
  20. Van Kerrebroeck P, Kreder K, Jonas U et aler N, Wein A; on behalf of the Tolterodine Study Group: Tolterodine once daily: superior efficacy
  21. and tolerability in the treatment of the overactive bladder. Urol 2001, 57, 414.
  22. Wagner TH, Hu TW, Bentkover J, LeBlanc K et al: Health – related consequences of overactive bladder. Am J Manag Care 2002, 8, 598-607.
  23. Abrams P, Andersson KE: Muscarinic receptor antagonists for overactive bladder. BJU Int 2007, 100, 987-1006.


Andrzej Wróbel
II Klinika Ginekologii
ul. Jaczewskiego 8
20-954 Lublin
tel. kom. 691 376 307